2-CHLORODEOXYADENOSINE IS AN ACTIVE SALVAGE THERAPY IN ADVANCED INDOLENT NON-HODGKINS-LYMPHOMA

被引：72

作者：

HOFFMAN, M ^{[1
]}

TALLMAN, MS ^{[1
]}

HAKIMIAN, D ^{[1
]}

JANSON, D ^{[1
]}

HOGAN, D ^{[1
]}

VARIAKOGIS, D ^{[1
]}

KUZEL, T ^{[1
]}

GORDON, LI ^{[1
]}

RAI, K ^{[1
]}

机构：

[1] NORTHWESTERN UNIV,SCH MED,CHICAGO,IL

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1994年 / 12卷 / 04期

关键词：

D O I：

10.1200/JCO.1994.12.4.788

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: To determine the response rate to 2-chlorodeoxyadenosine (2-CdA; cladribine) in patients with advanced indolent non-Hodgkin's lymphoma (NHL) who fail to respond to or progress after a response to standard chemotherapy drugs. Patients and Methods: Twenty-one patients were treated with at least one cycle of 2-CdA 0.1 mg/kg/d by continuous infusion for 5 or 7 days. Results: The overall response rate (complete response [CR] and partial response [PR]) was nine of 21 patients (43%; 95% confidence interval, 22% to 64%). Unmaintained durable responses (longest follow-up, 29+ months) have been observed. The treatment was well tolerated by all patients. The major toxicity was related to myelosuppression (predominantly neutropenia) and immunosuppression with infection. Conclusion: The purine analog 2-CdA is an active salvage therapy in pretreated patients with indolent NHL, and deserves further assessment in untreated patients and in combination with other chemotherapy agents.

引用

页码：788 / 792

页数：5

共 19 条

[1] CLINICAL-FEATURES AND PROGNOSIS OF FOLLICULAR LARGE-CELL LYMPHOMA - A REPORT FROM THE NEBRASKA-LYMPHOMA-STUDY-GROUP [J].